Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 8/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194084 | 0.94 | CCNA2 (0.51) | MKNK1CCNA2CDK2CCNA1KDR | |
| SCHEMBL2195692 | 0.94 | MKNK1 (0.41) | CCR2MKNK1CCNA2CDK2CCNA1 | |
| SCHEMBL2195687 | 0.94 | MKNK1 (0.41) | CCR2MKNK1CCNA2CDK2CCNA1 | |
| SCHEMBL2196635 | 0.92 | EGFR (0.44) | MKNK1KDREPHA2EPHB4EGFR | |
| SCHEMBL2195327 | 0.91 | EGFR (0.41) | CCR2MKNK1CCNA2CDK2CCNA1 | |
| SCHEMBL2194225 | 0.91 | MKNK1 (0.55) | MKNK1CCNA2CDK2CCNA1KDR | |
| SCHEMBL2199148 | 0.90 | EGFR (0.40) | MKNK1CCNA2CDK2CCNA1KDR | |
| SCHEMBL2191363 | 0.89 | TNNI3K (0.40) | MKNK1KDREGFRTNNI3KAURKA | |
| SCHEMBL2194979 | 0.89 | EGFR (0.46) | MKNK1KDREPHA2EPHB4EGFR | |
| SCHEMBL2194064 | 0.89 | EGFR (0.48) | KDREGFRAURKAERBB2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | CCR2 2909/4885MKNK1 2581/4885CCNA2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.